Inventor · disambiguated record
Peter Flynn
Also filed as: FLYNN PETER · FLYNN PETER F
18 granted patents·13 pending applications·183 citations·filing 1999–2022
93Inventor score
Files withARTIVA BIOTHERAPEUTICS INC9FATE THERAPEUTICS INC7UNIV YALE4LEE TOM TONG3ALEXION CAMBRIDGE CORP1
Top patents by PatentIndex Score
31 records- 0196US10023879B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2015·Granted Jul 17, 2018·13 cites·23 claims
- 0295US10954529B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2018·Granted Mar 23, 2021·8 cites·15 claims
- 0394US10844356B2Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsFATE THERAPEUTICS INC·Filed 2017·Granted Nov 24, 2020·7 cites·20 claims
- 0493US7981843B2Antibody specificity transfer using minimal essential binding determinantsKALOBIOS PHARMACEUTICALS INC·Filed 2005·Granted Jul 19, 2011·36 cites·14 claims
- 0588US9732319B2Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsVALAMEHR BAHRAM·Filed 2011·Granted Aug 15, 2017·10 cites·13 claims
- 0688US7964705B2Humaneered anti-factor B antibodyTALIGEN THERAPEUTICS INC·Filed 2008·Granted Jun 21, 2011·24 cites·4 claims
- 0787US11268069B2Reprogramming methods and cell culture platformsFATE THERAPEUTICS INC·Filed 2015·Granted Mar 8, 2022·4 cites·13 claims
- 0879US6486672B1High-resolution NMR spectroscopy of molecules encapsulated in low-viscosity fluidsFiled 2001·Granted Nov 26, 2002·40 cites·3 claims
- 0977US12152085B2Compositions and methods to regulate Renalase in the treatment of cancerUNIV YALE·Filed 2022·Granted Nov 26, 2024·0 cites·9 claims
- 1074US12264322B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2021·Granted Apr 1, 2025·0 cites·23 claims
- 1173US12415989B2Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsFATE THERAPEUTICS INC·Filed 2020·Granted Sep 16, 2025·0 cites·11 claims
- 1270US10273311B2Compositions to regulate renalase in the treatment of diseases and disordersUNIV YALE·Filed 2015·Granted Apr 30, 2019·1 cites·8 claims
- 1369US11370846B2Compositions and methods to regulate Renalase in the treatment of cancerUNIV YALE·Filed 2020·Granted Jun 28, 2022·0 cites·8 claims
- 1467US2022228125A1Reprogramming methods and cell culture platformsFATE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1564US10618975B2Antibody to RenalaseUNIV YALE·Filed 2019·Granted Apr 14, 2020·0 cites·8 claims
- 1658US9403885B2Wnt compositions and therapeutic uses of such compositionsLEE TOM TONG·Filed 2012·Granted Aug 2, 2016·1 cites·18 claims
- 1758US2024424099A1Treatment of cancer with nk cells and multispecific engagersARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1856US6198281B1NMR spectroscopy of large proteinsUNIV NEW YORK STATE RES FOUND·Filed 1999·Granted Mar 6, 2001·39 cites·12 claims
- 1953US2025073264A1Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the sameARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2052US2024180962A1Treatment of cancer with nk cells and a cd20 targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2150US2024366663A1Chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the sameARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2248US9096677B2Humaneered anti-factor B antibodyALEXION CAMBRIDGE CORP·Filed 2012·Granted Aug 4, 2015·0 cites·22 claims
- 2348US2024366664A1Treatment of cancer with nk cells and an egfr targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2448US2024197778A1Treatment of cancer with nk cells and a her2 targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2547US2024115704A1Treatment of cancer with nk cells and a cd38-targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2647US2024000840A1Treatment of cancer with nk cells and a cd20 targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2747US2024060046A1Expanded and stimulated natural killer cellsARTIVA BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2846US2011318337A1Humaneered anti-factor b antibodyEMLEN WOODRUFF·Filed 2011·Application pending·0 cites
- 2939US2013189780A1Reprogramming compositionsSHOEMAKER DANIEL·Filed 2010·Application pending·0 cites
- 3038US9873722B2Wnt compositions and therapeutic uses of such compositionsLEE TOM TONG·Filed 2012·Granted Jan 23, 2018·0 cites·12 claims
- 3134US2014171625A1Cardiotrophin related molecules for enhanced therapeuticsLEE TOM TONG·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Flynn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →